Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sifi S P A is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are distributed across 3 distinct art units, which suggests that the company's intellectual property covers multiple specialized sub-sectors within the broader field. The prosecution involves 3 distinct examiners, creating a diversified interaction with the patent office. This distribution of 3 pending office actions ensures that the workload is not concentrated under a single individual.
WEBB, WALTER E is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Since the pending office actions are split among the 3 distinct examiners, the workload is balanced across the 3 distinct art units. This distribution means that each examiner is responsible for a unique portion of the Biotechnology & Pharmaceuticals portfolio. Practitioners can expect to manage separate prosecution tracks, as the distinct art units likely represent different technical challenges or examination standards. The 1 pending office action assigned to WEBB, WALTER E will be subject to that examiner's specific procedural requirements. Coordinating strategies across the 3 distinct examiners is necessary to maintain consistency in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.3% | +60.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17802588 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Aug 26, 2022 |
| 17782207 | EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS | FERNANDEZ, SUSAN EMILY | 1651 | §103 | Final Rejection | 44d overdue | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSifi S P A has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Sifi S P A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
